Notably, splenic ablation has been associated with reduced TAM responses and delayed tumor growth.[25] In addition, CpG‐ODN can prompt monocytic myeloid‐derived suppressor cells (MDSCs) to differentiate into M1‐type macrophages and promote tumor elimination.[26] As a Toll‐like receptor 9 (TLR9) agonist, CpG‐ODN can stimulate the maturation and cytokine production of dendritic cells (DCs), to enhance the antitumor immune response. The gene discussed is TLR9; the disease is neoplasm.